Circulating miR34a levels as a potential biomarker in the follow-up of Ewing sarcoma.
Circulating biomarkers
Ewing sarcoma
Metastases
miR34a
miRNAs
Journal
Journal of cell communication and signaling
ISSN: 1873-9601
Titre abrégé: J Cell Commun Signal
Pays: Netherlands
ID NLM: 101308338
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
06
03
2020
accepted:
24
04
2020
pubmed:
7
6
2020
medline:
7
6
2020
entrez:
7
6
2020
Statut:
ppublish
Résumé
Appropriate tools for monitoring sarcoma progression are still limited. The aim of the present study was to investigate the value of miR-34a-5p (miR34a) as a circulating biomarker to follow disease progression and measure the therapeutic response. Stable forced re-expression of miR34a in Ewing sarcoma (EWS) cells significantly limited tumor growth in mice. Absolute quantification of miR34a in the plasma of mice and 31 patients showed that high levels of this miRNA inversely correlated with tumor volume. In addition, miR34a expression was higher in the blood of localized EWS patients than in the blood of metastatic EWS patients. In 12 patients, we followed miR34a expression during preoperative chemotherapy. While there was no variation in the blood miR34a levels in metastatic patients at the time of diagnosis or after the last cycle of preoperative chemotherapy, there was an increase in the circulating miR34a levels in patients with localized tumors. The three patients with the highest fold-increase in the miR levels did not show evidence of metastasis. Although this analysis should be extended to a larger cohort of patients, these findings imply that detection of the miR34a levels in the blood of EWS patients may assist with the clinical management of EWS.
Identifiants
pubmed: 32504411
doi: 10.1007/s12079-020-00567-2
pii: 10.1007/s12079-020-00567-2
pmc: PMC7511499
doi:
Types de publication
Journal Article
Langues
eng
Pagination
335-347Subventions
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : IG 18451
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : fellowship "SITE" 19498
Organisme : PROVABES
ID : PER-2011-2353839
Références
Pediatr Blood Cancer. 2018 Jan;65(1):
pubmed: 28868758
Nat Rev Clin Oncol. 2014 Mar;11(3):145-56
pubmed: 24492836
Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):10149-54
pubmed: 18626011
Cancer Res. 2018 Jun 15;78(12):3337-3349
pubmed: 29615432
Cancer Med. 2019 Mar;8(3):1086-1094
pubmed: 30790456
Sci Rep. 2017 Dec 20;7(1):17949
pubmed: 29263373
J Clin Oncol. 2015 Sep 20;33(27):3036-46
pubmed: 26304893
Clin Chem. 2016 Feb;62(2):328-34
pubmed: 26637479
JAMA. 2014 Jan 22-29;311(4):392-404
pubmed: 24449318
Cancer Cell. 2017 Feb 13;31(2):172-179
pubmed: 28196593
Cell Death Dis. 2017 Oct 12;8(10):e3100
pubmed: 29022903
PLoS One. 2017 Nov 1;12(11):e0186275
pubmed: 29091716
Int J Mol Sci. 2019 Nov 05;20(21):
pubmed: 31694149
Oncol Lett. 2019 Nov;18(5):5549-5554
pubmed: 31612063
Cancer Cell. 2012 Sep 11;22(3):291-303
pubmed: 22975373
Cancer Cell. 2014 Nov 10;26(5):668-681
pubmed: 25453903
Nat Rev Clin Oncol. 2013 Aug;10(8):472-84
pubmed: 23836314
Eur J Cancer. 2002 Nov;38(17):2243-51
pubmed: 12441260
Cancer Metastasis Rev. 2020 Mar;39(1):211-233
pubmed: 31970590
J Clin Med. 2019 Oct 16;8(10):
pubmed: 31623224
J Clin Oncol. 2014 Feb 20;32(6):579-86
pubmed: 24449238
Oncogene. 2017 Jun 22;36(25):3505-3514
pubmed: 28135250
Nat Med. 2017 Mar;23(3):386-395
pubmed: 28134926
Cell Signal. 2015 Mar;27(3):443-52
pubmed: 25499621
Acta Oncol. 2018 Apr;57(4):534-540
pubmed: 29117758
J Pathol. 2012 Apr;226(5):796-805
pubmed: 21960059
Cell Death Differ. 2011 Sep;18(9):1414-24
pubmed: 21415859
Int J Mol Sci. 2018 Oct 26;19(11):
pubmed: 30373199
Am J Pathol. 2013 Jul;183(1):3-9
pubmed: 23790801
Eur J Cancer. 2011 Mar;47(5):784-91
pubmed: 21112772
Nat Rev Clin Oncol. 2014 Mar;11(3):129-44
pubmed: 24445517
Int J Mol Sci. 2013 Sep 13;14(9):18925-58
pubmed: 24065096
Phys Med Biol. 2018 Mar 29;63(7):07TR01
pubmed: 29512515
Nat Rev Dis Primers. 2018 Jul 5;4(1):5
pubmed: 29977059
J Clin Invest. 2014 Apr;124(4):1853-67
pubmed: 24642471
Ann Oncol. 2014 Oct;25(10):2080-2086
pubmed: 25015333
Breast Cancer Res. 2010;12(6):R90
pubmed: 21047409
J Clin Oncol. 2003 Jan 1;21(1):85-91
pubmed: 12506175
Methods. 2010 Apr;50(4):298-301
pubmed: 20146939
J Surg Oncol. 2012 Dec;106(8):947-52
pubmed: 22648208
PLoS Genet. 2014 Jul 10;10(7):e1004475
pubmed: 25010205
Carcinogenesis. 2017 May 1;38(5):492-503
pubmed: 28334277
Front Oncol. 2016 Sep 07;6:202
pubmed: 27656422
Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):10660-10665
pubmed: 28923932
Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8
pubmed: 18663219
Clin Cancer Res. 2016 Sep 1;22(17):4356-65
pubmed: 27283964
Blood. 2018 Dec 13;132(24):2594-2607
pubmed: 30348653
J Exp Clin Cancer Res. 2019 Feb 4;38(1):53
pubmed: 30717802
J Clin Oncol. 1998 May;16(5):1707-11
pubmed: 9586882
Cancer Discov. 2014 Nov;4(11):1326-41
pubmed: 25186949
Cancer Discov. 2014 Nov;4(11):1342-53
pubmed: 25223734
Cancer. 2016 Oct;122(19):3015-23
pubmed: 27351911
J Clin Oncol. 1997 Feb;15(2):583-8
pubmed: 9053480
Ann Oncol. 2011 May;22(5):1221-1227
pubmed: 21059639
Int J Mol Sci. 2019 Aug 14;20(16):
pubmed: 31416192